Akero Therapeutics Inc Stock
Akero Therapeutics Inc Stock
With 2 Buy predictions and 1 Sell predictions the community is currently undecided on Akero Therapeutics Inc.
With a target price of 61 € there is a positive potential of 29.87% for Akero Therapeutics Inc compared to the current price of 46.97 €.
Our community identified positive and negative aspects for Akero Therapeutics Inc stock for the coming years. 2 users see the criterium "Revenue growth" as a plus for the Akero Therapeutics Inc stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Akero Therapeutics Inc in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akero Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akero Therapeutics Inc | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | -3.480% | -9.979% | -37.476% | -76.475% | -76.517% | -82.789% | -96.986% |
| Evolus Inc | -2.040% | 4.194% | 49.690% | 18.918% | 33.101% | -17.097% | -20.721% |
| Rhythm Pharmaceuticals | -1.600% | -2.500% | 5.978% | 17.470% | 4.278% | 313.136% | 837.500% |
Comments
Akero Therapeutics (NASDAQ:AKRO) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics (NASDAQ:AKRO) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics (NASDAQ:AKRO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $72.00 price target on the stock.
Show more
Ratings data for AKRO provided by MarketBeat